Gyre Therapeutics, Inc.GYRENASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank7
3Y CAGR-3.8%
5Y CAGR-43.1%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-3.8%/yr
vs -92.8%/yr prior
5Y CAGR
-43.1%/yr
Recent acceleration
Acceleration
+89.1pp
Accelerating
Percentile
P7
Near historical low
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 5.10 | -47.1% |
| 2024 | 9.64 | -28.7% |
| 2023 | 13.51 | +136.1% |
| 2022 | 5.72 | -88.8% |
| 2021 | 51.28 | -39.9% |
| 2020 | 85.29 | - |
| 2019 | 0.00 | -100.0% |
| 2018 | 215991.70 | +30076.9% |
| 2017 | 715.75 | +132.1% |
| 2016 | 308.36 | - |